Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study

<p>Abstract</p> <p>Background</p> <p>The prolonged survival of individuals diagnosed with cancer has led to an increase in the number of secondary primary malignancies. We undertook to perform a definitive study to characterize and predict prognosis of multiple primary...

Full description

Bibliographic Details
Main Authors: Zeng Qing-An, Qiu Jiliang, Zou Ruhai, Li Yijie, Li Shengping, Li Binkui, Huang Pinzhu, Hong Jian, Zheng Yun, Lao Xiangming, Yuan Yunfei
Format: Article
Language:English
Published: BMC 2012-04-01
Series:BMC Cancer
Subjects:
Online Access:http://www.biomedcentral.com/1471-2407/12/148
Description
Summary:<p>Abstract</p> <p>Background</p> <p>The prolonged survival of individuals diagnosed with cancer has led to an increase in the number of secondary primary malignancies. We undertook to perform a definitive study to characterize and predict prognosis of multiple primary malignancies (MPM) involving hepatocellular carcinoma (HCC), due to the scarcity of such reports.</p> <p>Methods</p> <p>Clinicopathological data were analyzed for 68 MPM patients involving HCC, with 35 (target group) underwent curative liver resection. Additional 140 HCC-alone patients with hepatectomy were selected randomly during the same period as the control group.</p> <p>Results</p> <p>Of the 68 patients with extrahepatic primary malignancies (EHPM), 22 were diagnosed synchronously with HCC, and 46 metachronously. The most frequent EHPM was nasophargeal carcinoma, followed by colorectal and lung cancer. Univariate analysis demonstrated that synchronous (<it>P</it> = 0.008) and non-radical treatment for EHPM (<it>P</it> < 0.001) were significant risk factors associated with poorer overall survival (OS). While, Cox modeling revealed that the treatment modality for EHPM, but not the synchronous/metachronous determinant, was an independent factor for OS, and that therapeutic option for HCC was an independent factor for HCC-specific OS. Moreover, no HCC-specific overall and recurrence-free survival benefit were observed in the control group when compared with that of the target group (<it>P</it> = 0.607, <it>P</it> = 0.131, respectively).</p> <p>Conclusions</p> <p>Curative treatment is an independent predictive factor for OS and HCC-specific OS, and should been taken into account both for synchronous and metachronous patients. MPM patients involving HCC should not be excluded from radical resection for HCC.</p>
ISSN:1471-2407